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Objectives: There are very few published chronic myeloid 
leukaemia (CML) epidemiology studies in South-East Asia 
and no representative from Malaysia. 
 
Methods: This is a cross-sectional study of adult CML 
patients (citizen) in a single but representative centre in 
southern Sarawak. 
 
Results: Total 79 patients (Malay 39%, Chinese 30.4%, Iban 
17.7%, Bidayuh 12.7%) were identified from the databases. 
Median age at diagnosis was younger, 40, compared to 
developed countries due to population structure. M:F ratio 
was higher, 2.6:1 compared to other countries 1.3-1.7:1. 
Majority presented at chronic phase (89.5%), 
low/intermediate risk score (80%) and started imatinib (96%) 
as first line tyrosine kinase inhibitor (TKI), which 40% of them 
switched to other TKI due to intolerance (17%) and failure 
(including disease progression)/not achieving major 
molecular response (83%). Quantitative polymerase chain 
reaction (qPCR) assessment after three months of TKI 
treatment had higher positive predictive value to predict 
Imatinib failure, 75%, than qPCR assessment after six 
months of TKI treatment, 58%. Presenting phase, symptoms, 
signs and laboratory data were like most countries. 
Estimated prevalence and incidence of CML in southern 
Sarawak was 69.2/1,000,000 population at the Year 2016 
(similar to most developing countries) and 8.0/1,000,000 
population per year at the Year 2011-2016 (similar to most 
countries), respectively. The incidence increased with age 
and was lowest among Iban, 12.8 and highest among 
Chinese, 19.5, which was 4x higher than Chinese in China. 
The prevalence of different BCR-ABL1 transcript type was 
like other Asia countries  
 
Conclusion: Significant epidemiological differences on M:F 







Chronic myeloid leukaemia (CML) is a myeloproliferative 
neoplasm that originated in an abnormal pluripotent bone 
marrow (BM) stem  cell  and is  consistently  associated with the  
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BCR-ABL1 fusion gene located in the Philadelphia (Ph) 
chromosome.1 Philadelphia chromosome is the derivative 
chromosome 22 resulting from the translocation between the 
long arm of chromosomes 9 and 22, designated as 
t(9;22)(q34.12;q11.23). On chromosome 9, the v-abl Abelson 
murine leukaemia viral oncogene homolog 1 (ABL1) gene 
breaks, usually at the intron between exon 1a and exon a2 or 
between exon a2 and exon a3. On chromosome 22, the 
breakpoint cluster region (BCR) gene breaks, usually at a 
region called major breakpoint cluster region (M-BCR), i.e., 
the intron between exon e13 and e14 or exon e14 and e15, 
which after translocation fused with ABL1 gene (at the exon 
a2 or exon a3) and remaining part from chromosome 9, 
resulting in a fusion gene, BCR-ABL1 (e13a2, e13a3, e14a2 or 
e14a3), which produce 210 kilodalton protein, designated as 
p210BCR-ABL1. Much less found in CML, when BCR gene breaks at 
minor breakpoint cluster region (m-BCR) or micro 
breakpoint cluster region (µ-BCR), it would result in a fusion 
gene, BCR-ABL1 (e1a2 or e1a3) or BCR-ABL1 (e19a2 or 
e19a3), which produce 190 or 230 kilodalton protein, 
designated as p190BCR-ABL1 or p230BCR-ABL1, respectively.2 These 
proteins were an abnormal kinase, Tyrosine Kinase, that 
apparently was the stimulant for the proliferation of myeloid 
cells to produce CML. 
 
The first Tyrosine Kinase Inhibitor (TKI), Imatinib (Glivec® or 
Gleevec®, Novartis Pharmaceuticals Corporation), was 
approved by the United State Food and Drug Administration 
at 2001.3 The invent of TKI has changed the paradigm of CML 
treatment and revolutionised the direction of oncology. 
Secondary (Nilotinib, Tasigna®, Novartis Pharmaceuticals 
Corporation; Dasatinib, Sprycel®, Bristol-Myers Squibb) and 
third generation TKI (Bosutinib, Bosulif®, Pfizer Inc.; 
Ponatinib, Iclusig®, ARIAD Pharmaceuticals, Inc.) are now 
available for clinical use. In Malaysia, Imatinib was available 
starting around 2000 under trial. Later, majority of patients 
from hospital in Ministry of Health (MOH), Ministry of Higher 
Education (MOHE) or private sector received Imatinib free of 
charge via Glivec International Patient Assistance Program 
(GIPAP), which officially started in 2003 and managed by Max 
Foundation (MF), a non-profit cancer organisation (personal 
communication with Dr Ong Tee Chuan). Very minority self-
purchased Imatinib, which the cost per month was around 
two times of the 2014 median monthly household income.4 
Imatinib supply for patients in MOH hospitals experienced 
smooth transition on 29th Nov 2007 from GIPAP to Malaysia 
Patient  Assistance  Program  (MYPAP),  which  meant  Malaysia’s 
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